 |
27 October 2023
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Block Listing Six Monthly Return
Avacta Group plc (AIM: AVCT), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Avacta Group plc | |||
| Name of scheme: | EMI scheme | |||
| Period of return: | From: | 28 April 2023 | | 27 October 2023 |
| Balance of unallotted securities under scheme(s) from previous return: | 414,178 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 600,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 216,256 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 797,922 | |||
| | | | | |
| Name of applicant: | Avacta Group plc | |||
| Name of scheme: | LTIP scheme | |||
| Period of return: | From: | 28 April 2023 | | 27 October 2023 |
| Balance of unallotted securities under scheme(s): | 2,370,589 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 3,700,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 793,332 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 5,277,257 | |||
| | | | | |
| Name of contact: | Tony Gardiner, Company Secretary |
| Telephone number of contact: | + 44 (0) 1904 217070 |
Ends-
For further information from Avacta Group plc, please contact:
| Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director
| Tel: +44 (0) 1904 21 7070 |
| Stifel Nicolaus Europe Limited (Nomad and Joint Corporate Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / William Palmer-Brown
| Tel: +44 (0) 207 710 7600 |
| Peel Hunt (Joint Corporate Broker) James Steel / Chris Golden / Patrick Birkholm | Tel: +44 (0) 207 418 8900
|
| ICR Consilium (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta has two divisions: an oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division, which is executing on an M&A led growth strategy to create a full-spectrum diagnostics business focused on supporting healthcare professionals and broadening access to testing. Avacta's two proprietary platforms, Affimer® and pre|CISION? underpin its cancer therapeutics whilst the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets.
The pre|CISION? platform modifies chemotherapy to be activated only in the tumour tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumours compared with healthy tissues, turning chemotherapy into a "precision medicine". The lead pre|CISION? programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.
Affimer® is a novel biologic platform which has significant technical and commercial advantages compared with antibodies and is used both to develop advanced immunotherapies and to improve the performance of immunodiagnostics.
With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit.
To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.